Clinical trials: Priming
Melanoma (Skin)
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085423
- Testing
- aldesleukin, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Coronary Artery Disease
Vis-Rx Prime Micro-Imaging Catheter Study
To study the performance of the Gentuity® HF-OCT (High Frequency Optical Coherence Tomography) Imaging System and Vis-Rx Prime® Micro-Imaging Catheter when used to obtain images of coronary arteries in patients who are undergoing…
- Trial name
- NCT06685783
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Gentuity, LLC
Ebola Viral Disease
A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
- Trial name
- NCT02416453
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- 11 sites in France, United Kingdom
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Infections, Streptococcal, Streptococcus Pneumoniae
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously…
- Trial name
- NCT00907777
- Testing
- Pneumococcal conjugate vaccine GSK 1024850A, Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)
- Where
- 17 sites in Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
A prospective, multi-center, single-arm study to establish the safety and effectiveness of the XIENCE V® Everolimus Eluting Coronary Stent, XIENCE nano™ Everolimus Eluting Coronary Stent, XIENCE PRIME™ LL Everolimus Eluting…
- Trial name
- EXPERT CTO (NCT01435031)
- Testing
- CTO Treatment Device
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Abbott Medical Devices
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
This phase II trial studies how well pembrolizumab and tamoxifen with or without vorinostat work for the treatment of estrogen receptor positive breast cancer.
- Trial name
- NCT04190056
- Testing
- Pembrolizumab, Tamoxifen, Vorinostat
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Bronchopulmonary Dysplasia
Pragmatic Research on Diuretic Management in Early BPD Pilot
Babies who are born prematurely often develop a chronic lung disease called bronchopulmonary dysplasia (BPD). BPD puts babies at higher risk for problems with growth and development.
- Trial name
- PRIMED (NCT05898022)
- Testing
- Furosemide (plus potassium chloride)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Healthy
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with…
- Trial name
- NCT02788045
- Testing
- Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140
- Where
- 10 sites in United States, Rwanda
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
HIV
A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults
This is an open-label, dose-escalation study to examine the safety, tolerability, and immunogenicity of adjuvanted Fusion Peptide Vaccine alone or in prime-boost regimens with adjuvanted Trimer 4571 and Trimer 6931 vaccines in…
- Trial name
- NCT05470400
- Testing
- FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg)
- Where
- 6 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Therapeutic Vaccine
Therapeutic Vaccine for HIV
Background: In most people who have human immunodeficiency virus (HIV), the immune system cannot control or cure the infection. Antiretroviral therapy drugs can keep the amount of HIV virus low for a long time.
- Trial name
- NCT01859325
- Testing
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetic Foot Ulcer
GrafixPL PRIME Evaluation Case Study
The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and GrafixPL…
- Trial name
- NCT03742440
- Testing
- GrafixPL PRIME
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Texas Southwestern Medical Center
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)